Home›Stock Screener›Gufic BioSciences

Gufic BioSciences Share Price Today | Stock Price & Gufic BioSciences Share Screener

GUFICBIO Pharmaceuticals
Live Share Price NSE
₹419.70
▲ 1.30 (0.31%)
2026-10-05 00:00:00
Live Share Price BSE
₹420.55
▲ 2.35 (0.56%)
2026-10-05 00:00:00

As of October 5, 2026, the live Gufic BioSciences share price (NSE: GUFICBIO) is ₹419.70 on NSE and ₹420.55 on BSE, up 0.31% from the previous close, with shares trading between ₹410.55 and ₹425.20 in today's trading session, and a 52-week range of ₹273.50–₹448.00. Check GUFICBIO 52-week high low for the annual price range and momentum. Use the Gufic BioSciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gufic BioSciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹261 and net income of ₹22, with EBITDA of ₹47, an operating margin of 18.0% and a profit margin of 8.4%.

Gufic BioSciences Market Cap ₹4,195.82 Cr.
GUFICBIO P/E Ratio (TTM) 58.98
Gufic BioSciences P/B Ratio 6.51
EPS (TTM) ₹6.40
Dividend Yield 0.02%
Debt to Equity 0.59
GUFICBIO 52 Week High ₹448.00
Gufic BioSciences 52 Week Low ₹273.50
Operating Margin 18.00%
Profit Margin 8.43%
GUFICBIO Revenue (TTM) ₹261.00
EBITDA ₹47.00
Net Income ₹22.00
Total Assets ₹1,342.00
Total Equity ₹665.00

Gufic BioSciences Share Price Chart

Track the current stock price of Gufic BioSciences with an interactive chart. Analyse GUFICBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gufic BioSciences stock quote in one place.

The quote of ₹419.70 sits between the 52-week low of ₹273.50 and the 52-week high of ₹448.00, and the latest session moved 0.31% from the previous close.

Gufic BioSciences Company Profile - Fundamental Screener

Screen Gufic BioSciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUFICBIO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE742B01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE742B01025

Gufic BioSciences Balance Sheet Screener

Screen GUFICBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,342, up from ₹1,169 in 2025.

Latest statistics put total assets at ₹1,342 and shareholder funds at ₹665, with a leverage ratio of 0.59.

Item 2026 2025 2024

Assets

Total Assets 1,342 1,169 1,093
Current Assets 802 625 601
Fixed Assets 491 506 159

Liabilities

Total Liabilities 0 0 0
Current Liabilities 160 181 188
Non-Current Liabilities 0 0 0

Shareholders' Equity

Total Equity 665 601 533
Share Capital 10 10 10
Reserves & Surplus 655 591 523

Gufic BioSciences Income Statement Screener - Profit & Revenue Analysis

Screen Gufic BioSciences income statement and profit fundamentals. Analyze GUFICBIO quarterly results. Gufic BioSciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹261 and net profit was ₹22, equal to earnings per unit of ₹2.22, at an operating margin of 18%.

In that period expenses were ₹214, interest cost ₹9 and tax ₹8. The next period listed, 2026-Mar, shows revenue of ₹251 and net profit of ₹22.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun

Revenue and Expenses

Revenue 261 251 232 239 225 205 210 204 204 196 202 215 196
Expenses 214 205 198 199 190 179 174 166 167 161 165 176 159

Operating Costs and Margins

EBITDA 47 46 34 40 34 27 36 39 37 35 37 40 36
Operating Profit % 18.00% 19.00% 14.00% 16.00% 15.00% 13.00% 16.00% 19.00% 18.00% 18.00% 18.00% 18.00% 18.00%
Depreciation 8 8 8 8 8 8 5 4 4 4 4 4 4
Interest 9 9 8 10 9 8 5 5 5 4 3 5 4

Profit and Earnings

Profit Before Tax 30 29 18 23 17 11 26 29 28 27 30 31 28
Tax 8 7 5 6 4 3 7 8 7 7 7 8 7
Net Profit 22 22 12 17 13 8 19 22 21 20 22 23 21
EPS 2.22 2.18 1.24 1.68 1.30 0.77 1.93 2.17 2.08 2.00 2.23 2.39 2.13

Gufic BioSciences Cash Flow Screener - Liquidity Fundamentals

Screen GUFICBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹45, and net cash flow was an inflow of ₹47.

Over the same period, investing activities used ₹31 and financing activities provided ₹32.

Item 2026-March 2025-March 2024-March

Cash from Operations and Investing

Operating Activities 45 123 -8
Investing Activities -31 -71 -102

Financing and Net Cash

Financing Activities 32 -37 82
Net Cash Flow 47 15 -28

Gufic BioSciences Shareholding Pattern Screener

See Gufic BioSciences shareholding pattern with promoter, FII, and DII holdings. Check Gufic BioSciences promoter holding and ownership changes for GUFICBIO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 72.50%, foreign institutions 0.42%, domestic institutions 3.83% and the public 13.93%, spread across 29,223 shareholders.

The shareholder count was 29,223 in 2026-Mar, compared with 29,753 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 72.50% 72.50% 72.51% 72.51% 72.50% 72.50% 72.51% 72.51%

Institutional Investors

FII Holding 0.42% 0.46% 0.31% 0.32% 0.34% 0.44% 0.12% 0.23%
DII Holding 3.83% 3.68% 3.39% 3.38% 3.65% 3.74% 2.20% 2.39%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 13.93% 14.00% 15.15% 15.10% 14.45% 14.13% 16.72% 16.36%
Other Holding 9.31% 9.36% 8.64% 8.70% 9.06% 9.19% 8.45% 8.52%
Shareholder Count 29,223 29,753 31,844 31,876 31,420 30,362 34,695 32,250

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gufic BioSciences. Gufic BioSciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.10 per unit for 2026-March, a yield of 0.02%, compared with ₹0.10 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.10, ₹0.10 and ₹0.10 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.10 0.02%
2025-March ₹0.10 0.04%
2024-March ₹0.10 0.03%
2023-March ₹0.10 0.04%
2022-March ₹0.10 0.05%
2021-March ₹0.10 0.04%
2020-March ₹0.05 0.04%
2019-March ₹0.05 0.10%
2018-March ₹0.05 0.07%
2017-March ₹0.05 0.05%

Gufic BioSciences Stock Index Membership - Nifty & Sensex

See which indices include Gufic BioSciences stock. Check GUFICBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Gufic BioSciences Market Events Screener - Corporate Actions

Get Gufic BioSciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gufic BioSciences stock events that may affect GUFICBIO share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 4, 2026, with a record date of September 4, 2026.

It is followed by Dividend dated August 28, 2026 and Quarterly Result Announcement dated August 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-04 2026-09-04 Annual General Meeting NA 9.05%
2026-08-28 2026-08-28 Dividend ₹ 0.10 /share 26.48%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 2.10%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 12.89%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 1.49%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -0.69%
2025-09-29 2025-09-29 Annual General Meeting NA -3.20%
2025-09-22 2025-09-22 Dividend ₹ 0.10 /share -5.49%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -2.72%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 2.75%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -4.73%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -7.61%
2024-09-25 2024-09-25 Annual General Meeting NA -0.95%
2024-09-17 2024-09-19 Dividend ₹ 0.10 /share 27.37%
2023-09-29 2023-09-29 Annual General Meeting NA -7.11%

Gufic BioSciences Competitors Screener - Peer Stocks Comparison

Screen GUFICBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Gufic BioSciences Company Announcements - News & Reports Screener

Screen GUFICBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 2, 2026.

The next most recent announcements are dated October 1, 2026 and October 1, 2026.

Date Update Actions
2026-10-02 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-01 Closure of Trading Window -
2026-10-01 Intimation Of Environmental Social And Governance (ESG) Rating -
2026-09-26 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-08 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-07 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-04 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-02 Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Promotion And Change In Designation Of Senior Management Personnel -
2026-08-21 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-08-14 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-14 Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026 -
2026-08-14 Board Meeting Outcome for Meeting Held On Friday August 14 2026 -
2026-08-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-12 Business Responsibility and Sustainability Reporting (BRSR) -
2026-08-12 Reg. 34 (1) Annual Report. -
2026-08-12 Intimation Of Record Date For Final Dividend And 42Nd Annual General Meeting -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹419.70, within a 52-week range of ₹273.50 to ₹448.00. The P/E ratio is 58.98 and the P/B ratio is 6.51, with earnings per unit of ₹6.40. Market capitalisation stands at ₹4,195.82 Cr and the dividend yield is 0.02%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 3 balance sheet periods, 13 income statement periods, 3 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.